Scarica l'app Stockscreener
1.57
3.29%
0.05
Precedente Chiudi:
$1.52
Aprire:
$1.54
Volume 24 ore:
708.28K
Relative Volume:
1.17
Capitalizzazione di mercato:
$67.20M
Reddito:
-
Utile/perdita netta:
$-77.27M
Rapporto P/E:
-0.7843
EPS:
-2.0019
Flusso di cassa netto:
$-66.29M
1 W Prestazione:
+9.03%
1M Prestazione:
-4.85%
6M Prestazione:
-30.53%
1 anno Prestazione:
+26.61%
Intervallo 1D:
$1.51
$1.61
Intervallo di 1 settimana:
$1.445
$1.62
Portata 52W:
$1.15
$3.56
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Nome
Acrivon Therapeutics Inc
Settore
Industria
Telefono
617-207-8979
Indirizzo
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.57 | 67.20M | 0 | -77.27M | -66.29M | -2.0019 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-05 | Ripresa | Piper Sandler | Overweight |
| 2025-01-31 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-12-15 | Ripresa | Jefferies | Buy |
| 2023-10-05 | Iniziato | Maxim Group | Buy |
| 2023-06-02 | Iniziato | Oppenheimer | Outperform |
| 2023-05-08 | Iniziato | BMO Capital Markets | Outperform |
| 2023-04-27 | Iniziato | Ladenburg Thalmann | Buy |
| 2023-04-20 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-12-12 | Iniziato | Jefferies | Buy |
| 2022-12-12 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie
Acrivon Therapeutics Stockholders Approve Amended 2022 Equity Incentive Plan and Elect New Directors – June 2026 - Minichart
Acrivon Therapeutics shareholders approve equity plan changes and director elections - Investing.com UK
Acrivon Shareholders Approve Expanded Equity Plan and Directors - TipRanks
Acrivon amends equity plan, shareholders approve 3,000,000-share increase - TradingView
Acrivon Therapeutics (ACRV) shareholders approve larger equity plan and elect directors - Stock Titan
Acrivon Therapeutics Inc (ACRV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Acrivon Therapeutics Inc (ACRV) Institutional Confidence - TradingKey
Acrivon Therapeutics Inc (ACRV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Acrivon Therapeutics Inc (ACRV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Acrivon Therapeutics Inc (ACRV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ACRV Stock Price, Quote & Chart - ChartMill
Gabelli Initiates Acrivon Therapeutics(ACRV.US) With Buy Rating, Announces Target Price $8 - Moomoo
Acrivon Therapeutics Inc (ACRV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Acrivon Therapeutics (ACRV) Shows Modest Upside Amidst Key Technical LevelsDealer Delta - newsline.com
Acrivon Therapeutics (ACRV) Faces Continued Pressure, Testing Key Support After 7.7% DeclinePercent Above MA - newsline.com
Acrivon Therapeutics (ACRV) Slides 7.7% as Support Test Looms After Bearish MomentumDealer Positioning - newsline.com
ACRV Q1 2026 Earnings: EPS Beats Estimates as Clinical Pipeline AdvancesEPS Estimate Trend - newsline.com
ACRV Q1 2026 Earnings: Positive EPS Surprise Amid Pre-Revenue Pipeline ProgressEarnings Acceleration Picks - newsline.com
Acrivon Therapeutics (ACRV) Slides 1.23% as Stock Tests Key Support at $1.53Pairs Trade - The Legal Advocate
Acrivon Therapeutics Q1 2026 Earnings: Narrower Loss Per Share as Pipeline Progress ContinuesSurprise Factor Analysis - The Legal Advocate
Acrivon Therapeutics (ACRV) Edges Higher: Biotech Stock Tests Key Resistance at $1.77Double EMA - newsline.com
Acrivon (ACRV) CEO and EVP report RSU-related tax withholding move - Stock Titan
Acrivon Therapeutics (ACRV) Slides 1.71% as Stock Nears Critical Support ZoneDollar Neutral Pair - The Legal Advocate
Acrivon Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineDividend Increase Stocks - newsline.com
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline - Investing.com UK
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline By Investing.com - Investing.com Australia
Acrivon Therapeutics CEO to Participate in Virtual Fireside Chat at TD Cowen’s 7th Annual Oncology Innovation Summit - Quiver Quantitative
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit - The Manila Times
9,366 RSUs granted to Acrivon (ACRV) director for RA Capital funds - Stock Titan
Acrivon (ACRV) director receives 9,366 restricted stock units as equity award - Stock Titan
Director at Acrivon Therapeutics (ACRV) awarded 9,366 RSUs vesting 2027 - Stock Titan
Acrivon Therapeutics (ACRV) director receives 9,366 RSUs vesting in 2027 - Stock Titan
Acrivon (ACRV) director receives 9,366 restricted stock units in equity grant - Stock Titan
Acrivon Therapeutics (ACRV) CFO awarded 46,167 RSUs, holdings rise to 67,150 shares - Stock Titan
Acrivon Therapeutics (ACRV) director receives 9,366 RSUs award - Stock Titan
Acrivon Therapeutics (ACRV) director granted 9,366 restricted stock units - Stock Titan
Acrivon Therapeutics (ACRV) CAO awarded 14,227 RSUs in equity grant - Stock Titan
Acrivon Therapeutics (ACRV) CMO receives 38,817-share restricted stock unit grant - Stock Titan
Acrivon Therapeutics (ACRV) grants 49,830 RSUs to Chief Legal Officer Mary Miller - Stock Titan
Acrivon Therapeutics (ACRV) CDO receives 38,584-share RSU grant with staged vesting - Stock Titan
Acrivon (ACRV) COO Eric Devroe receives 72,981 RSU stock grant - Stock Titan
Acrivon Therapeutics (ACRV) leaders receive new RSU and stock grants - Stock Titan
Pleasing Signs As A Number Of Insiders Buy Acrivon Therapeutics Stock - simplywall.st
Acrivon (NASDAQ: ACRV) CLO has 184 shares withheld for RSU tax - Stock Titan
Acrivon Therapeutics (ACRV) CAO reports 99-share tax withholding on RSU vesting - Stock Titan
Acrivon (ACRV) CDO has 404 shares withheld to cover RSU tax liability - Stock Titan
[Form 4] Acrivon Therapeutics, Inc. Insider Trading Activity - Stock Titan
Acrivon (NASDAQ: ACRV) leaders use 1,743 shares for RSU tax withholding - Stock Titan
Maxim Group Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Acrivon Pharmaceuticals: Buy Rating Backed by Strong Cash Runway and Promising ACR-368 Phase 2 Efficacy - TipRanks
Number of shareholders of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView
Acrivon Therapeutics Inc Azioni (ACRV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):